Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12056033 | 1.00 | PPARA (0.32) | PPARAACLY | |
| SCHEMBL10259177 | 0.97 | ACLY (0.34) | PPARAACLY | |
| SCHEMBL5705657 | 0.97 | ACLY (0.34) | PPARAACLY | |
| SCHEMBL6204262 | 0.93 | ACLY (0.36) | PPARAACLY | |
| SCHEMBL10258424 | 0.93 | ACLY (0.36) | PPARAACLY | |
| SCHEMBL12056032 | 0.92 | — | — | |
| SCHEMBL5705541 | 0.92 | — | — | |
| SCHEMBL10266721 | 0.89 | ACLY (0.39) | PPARAACLY | |
| SCHEMBL6205879 | 0.89 | ACLY (0.39) | PPARAACLY | |
| SCHEMBL3332346 | 0.89 | ACLY (0.33) | PPARAACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1564200-A1 | Ketone compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| EP-1326822-A2 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | Esperion Therapeutics Inc. (US) | 2003-07-16 | — | — | EP | claimed |
| US-20030078239-A1 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2003-04-24 | — | — | US | claimed |
| WO-2002030860-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2003-02-20 | — | — | WO | claimed |
| WO-2002030860-A2 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2002-04-18 | — | — | WO | claimed |
| EP-1564200-A1 | Ketone compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078239-A1 | Ketone compounds and compositions for cholesterol management and related uses | PC, HMGCR, GPR119 | PPARA 27/4885ACLY 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.